hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06332261, orgStudyIdInfo id: 2024-BB-01, briefTitle: Standardized Assessment in Depression Treatment in Routine Psychiatric Services, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: Region Stockholm, descriptionModule briefSummary: The goal of this observational study is to evaluate current practices in depression treatment in psychiatric services in Stockholm, Sweden.The main questions it aims to answer are:* Are current practices consistent with local clinical guidelines in terms of standardized assessment and the treatments provided?* What are the present conditions for implementing measurement-based care in depression treatment in this setting?Data will be collected retrospectively from medical records of patients having received psychological or pharmacological treatment for depression from 2020 to 2023. Frequency of standardized assessments (not scores) using the Montgomery-Åsberg Depression Rating Scale, the Montgomery-Åsberg Depression Rating Scale-Self Assessment, and the Patient Health Questionnaire-9 is collected, together with information on patient, clinician, and treatment characteristics., conditionsModule conditions: Major Depressive Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 4000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Montgomery-Åsberg Depression Rating Scale, secondaryOutcomes measure: Montgomery-Åsberg Depression Rating Scale-Self Assessment, secondaryOutcomes measure: The Patient Health Questionnaire-9, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stockholm Health Care Services, Region Stockholm, city: Stockholm, country: Sweden, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06332235, orgStudyIdInfo id: KMUHIRB-F(I)-20220023, briefTitle: Efficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Taiwanese Population., statusModule overallStatus: RECRUITING, startDateStruct date: 2022-02-18, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Kaohsiung Medical University Chung-Ho Memorial Hospital, class: OTHER, descriptionModule briefSummary: To evaluate the therapeutic effects and safety of silodosin in the patients of acute brain injury with lower urinary tract symptoms., conditionsModule conditions: Human Trichinellosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Silodosin 8 mg, outcomesModule primaryOutcomes measure: Assessment criteria Efficacy, primaryOutcomes measure: Assessment criteria Safety, secondaryOutcomes measure: Assessment criteria Efficacy, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kaohsiung Medical University Chung-Ho Memorial Hospital, status: RECRUITING, city: Kaohsiung, state: Sanmin District, zip: 807, country: Taiwan, contacts name: Chen Yu Chen, MS, role: CONTACT, phone: 0911884597, email: jennis7995@hotmail.com, geoPoint lat: 22.61626, lon: 120.31333, hasResults: False
protocolSection identificationModule nctId: NCT06332222, orgStudyIdInfo id: 1987, briefTitle: Recovery With Tart Cherry Supplementation Following a Marathon., statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2023-10-11, completionDateStruct date: 2023-10-11, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Northumbria University, class: OTHER, collaborators name: Iprona Lana SpA, descriptionModule briefSummary: The goal of this clinical trial is to compare recovery in healthy, active runners.The main questions it aimed to answer were whether 7 day supplementation with Vistula TC attenuated:* muscle function* inflammation* soreness following a marathon run.Participants will either consume a spray-dried tart cherry supplement or a calorie-matched placebo-control for 7 days, and complete a marathon. Participants will perform functional tests, be assessed for their perceptual recovery and markers of inflammation and muscle damage via:* maximal voluntary contractions* counter movement jumps* visual analog scales to assess soreness* blood samples, conditionsModule conditions: Exercise Recovery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 35, type: ACTUAL, armsInterventionsModule interventions name: Tart Cherry, interventions name: Placebo, outcomesModule primaryOutcomes measure: Maximal Voluntary Contraction, secondaryOutcomes measure: Counter Movement Jump, secondaryOutcomes measure: Active Muscle Soreness, secondaryOutcomes measure: Serum Concentration of High-Sensitive C-Reactive Protein, secondaryOutcomes measure: Serum Concentration of Creatine Kinase, secondaryOutcomes measure: Perceptual Measures, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Northumbria University, city: Newcastle Upon Tyne, state: Tyne And Wear, zip: NE1 8ST, country: United Kingdom, geoPoint lat: 54.97328, lon: -1.61396, hasResults: False
protocolSection identificationModule nctId: NCT06332209, orgStudyIdInfo id: Pro00135303, secondaryIdInfos id: U66RH31458, type: OTHER_GRANT, domain: Telehealth Center of Excellence, briefTitle: Randomized Trial of Tele Vs. Clinic TF-CBT in Puerto Rico, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Medical University of South Carolina, class: OTHER, descriptionModule briefSummary: The current study will evaluate TF-CBT delivered via tele-health for youth presenting with trauma symptoms via a randomized controlled trial. Goals of the current study are to examine the effectiveness of Tele-TF-CBT delivered by community providers in Puerto Rico in improving youth trauma outcomes. Goals are also to support the feasibility, acceptability, and engagement outcomes of Tele-health delivery., conditionsModule conditions: Post-Traumatic Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Trauma Focused Cognitive Behavioral Therapy, outcomesModule primaryOutcomes measure: Traumatic Stress Symptoms, primaryOutcomes measure: Traumatic Stress Symptoms, secondaryOutcomes measure: Anxiety and Depression Symptoms, secondaryOutcomes measure: Anxiety and Depression Symptoms, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06332183, orgStudyIdInfo id: ECDGWAS, briefTitle: GWAS and EWAS in Patients With Erdheim-Chester Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-07-17, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Augusto Vaglio, class: OTHER, descriptionModule briefSummary: Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the condition are still unknown, and although some mutations in genes involved in cell proliferation have been identified, other factors may be involved. Susceptibility to developing rare diseases like ECD is typically associated with genetic factors, including DNA polymorphisms and epigenetic modifications.This study aims to analyze the entire genome of a large cohort of patients with ECD and healthy controls to determine whether there are polymorphisms and epigenetic variants associated with susceptibility to developing the disease. The study could thus clarify the genetic predisposition to ECD development, provide insights into disease pathogenic mechanisms, and identify proteins or cellular mechanisms potentially targeted by specific treatments., conditionsModule conditions: Erdheim-Chester Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Presence of polymorphisms, outcomesModule primaryOutcomes measure: Polymorphisms and genetic variants correlated with disease development, primaryOutcomes measure: Methylation in Erdheim-Chester disease, primaryOutcomes measure: Gene expression in Erdheim-Chester disease, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 99 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hopital Pitié Salpetrière, status: RECRUITING, city: Paris, country: France, contacts name: Julien Haroche, role: CONTACT, geoPoint lat: 48.85341, lon: 2.3488, locations facility: Meyer Children's Hospital IRCCS, status: RECRUITING, city: Florence, country: Italy, contacts name: Augusto Vaglio, role: CONTACT, email: augusto.vaglio@meyer.it, geoPoint lat: 43.77925, lon: 11.24626, locations facility: IRCCS Ospedale San Raffaele, status: RECRUITING, city: Milano, country: Italy, contacts name: Lorenzo Dagna, role: CONTACT, geoPoint lat: 45.46427, lon: 9.18951, locations facility: AOU Parma, status: RECRUITING, city: Parma, country: Italy, contacts name: Davide Martorana, role: CONTACT, geoPoint lat: 44.79935, lon: 10.32618, locations facility: Genetics Lab, CSIC, status: RECRUITING, city: Granada, country: Spain, contacts name: Javier Martin, role: CONTACT, geoPoint lat: 37.18817, lon: -3.60667, hasResults: False
protocolSection identificationModule nctId: NCT06332170, orgStudyIdInfo id: HS-20093-103, briefTitle: ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2026-05-30, completionDateStruct date: 2028-05-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Hansoh BioMedical R&D Company, class: INDUSTRY, descriptionModule briefSummary: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients., conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 610, type: ESTIMATED, armsInterventionsModule interventions name: HS-20093, interventions name: Adebrelimab, interventions name: Cisplatin/ Carboplatin, interventions name: Cetuximab, interventions name: Enzalutamide, outcomesModule primaryOutcomes measure: Maximum tolerated dose (MTD) for combination-treatments, secondaryOutcomes measure: Incidence and severity of adverse events (AEs), secondaryOutcomes measure: Objective response rate (ORR) determined by investigators, secondaryOutcomes measure: Disease control rate (DCR) determined by investigators, secondaryOutcomes measure: Duration of response (DoR) determined by investigators, secondaryOutcomes measure: Progression-free survival (PFS) determined by investigators according to RECIST 1.1, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Radiographic progression-free survival (rPFS) determined by investigators according to RECIST 1.1 and PCWG3, secondaryOutcomes measure: Time to PSA progression (TTPP), secondaryOutcomes measure: Prostate-specific cancer antigen (PSA) response rate, secondaryOutcomes measure: Time to first subsequent therapy (TFST), secondaryOutcomes measure: Observed maximum plasma concentration (Cmax) of HS-20093advanced solid tumor, secondaryOutcomes measure: Time to reach maximum plasma concentration (Tmax) of HS-20093, secondaryOutcomes measure: Terminal half-life (T1/2) of HS-20093 following the first dose, secondaryOutcomes measure: Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093, secondaryOutcomes measure: Percentage of participants with antibodies to HS-20093 in serum, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06332157, orgStudyIdInfo id: 2023-ke-715-1, briefTitle: Postoperative Quality of Recovery After General Anesthesia With Remimazolam, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Beijing Chao Yang Hospital, class: OTHER, descriptionModule briefSummary: 126 patients undergoing general anesthesia for elective surgery in Beijing Chaoyang Hospital were selected. In the intervention group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min; Anesthesia was maintained with 1.0-2.0mg/min remimazolam besylate by continuous pump. Control group: anesthesia induction, intravenous injection of propofol 2mg/kg; Anesthesia was maintained by continuous pumping of 6-8mg/kg/h propofol. All patients were routinely monitored for vital signs and anesthesia depth after entering the operating room. The patients were followed up after surgery, and the quality of recovery score at 24 hours after surgery was the main study outcome., conditionsModule conditions: Anesthesia Recovery Period, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 126, type: ESTIMATED, armsInterventionsModule interventions name: Remimazolam besylate, interventions name: Propofol Injection Emulsion, outcomesModule primaryOutcomes measure: 15-item quality of recovery scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06332131, orgStudyIdInfo id: UPCC07623, briefTitle: Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Abramson Cancer Center at Penn Medicine, class: OTHER, descriptionModule briefSummary: This is an observational study that includes patients with melanoma who will be treated with adjuvant immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system., conditionsModule conditions: Melanoma, conditions: Coronary Microvascular Dysfunction, conditions: Cardiotoxicity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 25, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidence of new abnormal myocardial blood flow reserve (MBFR), secondaryOutcomes measure: Incidence of major cardiovascular events, secondaryOutcomes measure: Coronary calcium score, secondaryOutcomes measure: All cause mortality, secondaryOutcomes measure: Cardiovascular specific mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Abramson Cancer Center at University of Pennsylvania, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06332118, orgStudyIdInfo id: avf ice massage, briefTitle: The Effect of Ice Massage on Pain, Ecchymosis, Hematoma and Patient Satisfaction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Erzurum Technical University, class: OTHER, descriptionModule briefSummary: The research was planned to measure pain, ecchymosis, hematoma and patient satisfaction with ice massage applied to the fistula before the arteriovenous fistula procedure in hemodialysis patients. Patients who agree to participate in the study will be given ice massage before the procedure and the relevant parameters will be measured., conditionsModule conditions: Hemodialysis Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The research is quasi-experimental and relationship-seeking in a pretest-posttest format., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: ice massage group, outcomesModule primaryOutcomes measure: Pain score, secondaryOutcomes measure: Ecchymosis degree, secondaryOutcomes measure: Hematoma degree, secondaryOutcomes measure: Patient satisfaction score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ercan Bakır, city: Erzurum, state: Yakutiye, zip: 25010, country: Turkey, contacts name: Ercan Bakır, PhD, role: CONTACT, phone: 05444252111, email: ercan.bakir@erzurum.edu.tr, contacts name: Ercan Bakır, PhD, role: CONTACT, phone: 05443047186, email: e.bakir02@gmail.com, geoPoint lat: 39.90861, lon: 41.27694, locations facility: Ercan Bakır, city: Erzurum, state: Yakutiye, country: Turkey, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06332105, orgStudyIdInfo id: CUK001, briefTitle: Evaluation of Low Phenylalanine Formulas, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-30, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Ajinomoto Co., Inc., class: INDUSTRY, collaborators name: Birmingham Children's Hospital, collaborators name: Great Ormond Street Hospital for Children NHS Foundation Trust, descriptionModule briefSummary: Ajinomoto Cambrooke has developed a PKU protein substitute that is a proprietary blend of purified Glycomacropeptide (GMP) and essential amino acids, under the brand name Glytactin®. One serving of such Glytactin® products contains 20mg or less of Phenylalanine (Phe). The aim of the proposed study is to use this purified GMP-AA-based protein substitute, with less Phe per gram of protein equivalent than other commercially available products, in children with PKU at 100% of their protein substitute intake and evaluate its efficacy and the change in blood Phe in comparison to Phe-free L-AA-based protein substitutes., conditionsModule conditions: Phenylketonurias, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: 2-stage, 15-week randomized crossover trial., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 19, type: ESTIMATED, armsInterventionsModule interventions name: Glytactin, interventions name: L-AA, outcomesModule primaryOutcomes measure: Change in blood Phe in, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Birmingham Women and Children's Hospital, city: Birmingham, state: West Midlands, zip: B4 6NH, country: United Kingdom, geoPoint lat: 52.48142, lon: -1.89983, locations facility: Great Ormond Street Hospital for Children, city: London, zip: WC1N 3JH, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False